Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 5/20 | 0.62 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.57 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.56 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102127 | 0.91 | SRD5A2 (0.67) | PLA2G4ASRD5A2LTB4RLTB4R2 | |
| SCHEMBL13802519 | 0.84 | SRD5A2 (0.72) | PLA2G4ASRD5A2LTB4RLTB4R2 | |
| SCHEMBL2015584 | 0.80 | SRD5A2 (0.63) | PLA2G4ASRD5A2LTB4RLTB4R2 | |
| SCHEMBL13802531 | 0.78 | SRD5A2 (0.74) | PLA2G4ASRD5A2LTB4RLTB4R2 | |
| SCHEMBL2207104 | 0.77 | MCL1 (0.74) | SRD5A2LTB4RLTB4R2 | |
| SCHEMBL700511 | 0.76 | SRD5A2 (0.73) | PLA2G4ASRD5A2LTB4RLTB4R2 | |
| SCHEMBL4322740 | 0.74 | PLA2G4A (0.57) | PLA2G4ASRD5A2LTB4RLTB4R2 | |
| SCHEMBL4470968 | 0.73 | SRD5A2 (1.00) | PLA2G4ASRD5A2LTB4RLTB4R2 | |
| SCHEMBL3094280 | 0.73 | CYSLTR2 (0.51) | PLA2G4ASRD5A2 | |
| SCHEMBL2016346 | 0.73 | SRD5A2 (0.56) | SRD5A2LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318952-B2 | Substituted indole derivatives for the treatment of respiratory diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-27 | — | — | US | claimed |
| US-8318952-B2 | Substituted indole derivatives for the treatment of respiratory diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| EP-2481732-A1 | Condensed ring compound and use thereof | Ono Pharmaceutical Co., Ltd. (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20100234368-A1 | CONDENSED RING COMPOUND AND USE THEREOF | TAKEUCHI JUN | 2010-09-16 | — | — | US | disclosed |
| US-7763610-B2 | Carboxylic acid derived benzoxazines as agents for the treatment of respiratory diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-20060194797-A1 | Condensed ring compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1661892-A1 | CONDENSED RING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234368-A1 | CONDENSED RING COMPOUND AND USE THEREOF | CYSLTR2, CYSLTR1, LTB4R2 | PLA2G4A 257/4885SRD5A2 1033/4885LTB4R 5/4885 |
| US-20060194797-A1 | Condensed ring compound and use thereof | CYSLTR2, CYSLTR1, LTB4R2 | PLA2G4A 257/4885SRD5A2 1033/4885LTB4R 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.